AstraZeneca

Stamp of approval
#AstraZeneca #Cancer #Chemotherapy #Clinical research #MHRA #Oncology

First-line AZ treatment for adults with biliary tract cancer approved 

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to AstraZeneca for Imfinzi (durvalumab) in combination with gemcitabine and cisplatin in Great Britain for use as a first-line treatment of adults with locally advanced, unresectable or metastatic biliary tract cancer (BTC).1 This authorisation by… Read More

#Cancer Research #News

Woman using an asthma inhaler
#Asthma #AstraZeneca #Avillion #FDA #Phase III trial #United States

FDA approves first rescue medication to manage asthma inflammation

Airsupra (albuterol/budesonide) has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.  Airsupra is a pressurised metered-dose inhaler (pMDI), fixed-dose combination of albuterol, a short-acting beta2-agonist (SABA), and budesonide, an… Read More

#News #Regulatory

Patient checking own blood pressure
#Acquisition #AstraZeneca #Chronic kidney disease (CKD) #Hypertension #Mergers and acquisitions

AstraZeneca gains rights to novel aldosterone synthase inhibitor

AstraZeneca has entered into an agreement to acquire CinCor Pharma, a clinical-stage biopharmaceutical company, focused on developing treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.  As part of the deal, the company will acquire CinCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood… Read More

#Business & Investment #Editor's Choice #News

Antibodies attack Covid-19
#AstraZeneca #Covid-19 #Covid-19 treatment #Immunity #Monoclonal antibodies

Accelerated development for Covid-19 monoclonal antibody

A monoclonal antibody to prevent Covid-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery.  AstraZeneca has initiated the SUPERNOVA Phase I/III trial of AZD5156 (a combination of AZD3152 and cilgavimab) in pre-exposure prophylaxis of Covid-19, following the company licensing AZD3152 from… Read More

#Covid-19 #News #Trending News

#AstraZeneca #Biobanking #Covid-19 #Genetics #Genomics #Public health #Research

Podcast: Is genomic data the new frontier in drug discovery?

This is the latest episode of the free narrated DDW podcast, “Is genomic data the new frontier in drug discovery?” It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “Genomics boosts understanding of Covid-19 severity and susceptibility” and “… Read More

#News

MHRA
#AstraZeneca #Cardiovascular disease #Heart disease #MHRA

UK licence extension approved for AstraZeneca’s dapagliflozin

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin for the treatment of symptomatic chronic heart failure (HF).  The drug is approved in patients with HF and a left ventricular ejection fraction (LVEF) >40%, including HF with mildly reduced ejection fraction (HFmrEF) and… Read More

#News #Regulatory

Cambridge University
#AstraZeneca #Cambridge Innovation Park #Innovation #UK

AstraZeneca joins Cambridge scientific innovation committee

An initial 100 organisations have signed an agreement to support, promote and enhance innovation in the Greater Cambridge area.  Signatories to the ‘Innovate Cambridge Charter’ also hope to develop a set of ecosystem-wide initiatives that ensure Cambridge continues to compete effectively on the international stage in the… Read More

#News

Patient using a mammography machine
#AstraZeneca #Breast cancer #Cancer research #Phase III trial #Precision medicine #The Institute of Cancer Research

Targeted breast cancer drug extends lives of patients in Phase III trial

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major Phase III clinical trial.  The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most… Read More

#Cancer Research #News #Trending News

NHS Scotland A&E department
#AstraZeneca #Hyperkalaemia #Lokelma #NHS Scotland #Scottish Medicines Consortium (SMC)

Lokelma now available in emergency setting in Scotland

The Scottish Medicines Consortium (SMC) has updated its advice for AstraZeneca’s Lokelma (sodium zirconium cyclosilicate [SZC]) for adult patients with hyperkalaemia in Scotland.   Patients can now access SZC in the emergency care setting for the treatment of acute, life-threatening hyperkalaemia alongside standard care.  SZC is already used within NHS Scotland… Read More

#News #Regulatory

#AstraZeneca #Breast cancer #Institute of Cancer Research #Oncology

EMA approves early-stage breast cancer treatment  

A precision medicine for early-stage breast cancer has been approved by the European Medicines Agency (EMA).   Developed by AstraZeneca and Merck & Co (MSD) under the brand name Lynparza, the treatment is a precision medicine which blocks DNA damage response (DDR) in cells or tumours that have… Read More

#Cancer Research #News

#AstraZeneca #BioNTech #Covid-19 #Pfizer

Covid-19 vaccines remain effective six months after second dose

Two doses of Covid-19 vaccines were sufficient in providing protection against severe cases of the infectious disease, according to new research.  A study1 led by researchers at the University of Bristol found that two doses of Pfizer-BioNTech and AstraZeneca Covid-19 vaccines provided protection against Covid-19 infections six months… Read More

#Covid-19 #News

Back pain
#AstraZeneca #DNA #Oncology

Could this drug help repair nerve damage?  

Research from the University of Birmingham in the UK has indicated that a cancer therapy could help damaged nerves repair themselves following spinal injury.   The research shows that AstraZeneca’s candidate drug AZD1390 can block the response to DNA damage in nerve cells and promote regeneration of damaged… Read More

#News #Trending News

#AstraZeneca #Chronic kidney disease (CKD)

Kidney disease has considerable public impact, study says  

The burden of chronic kidney disease (CKD) in adult populations has found to be greater than previously estimated, according to the latest real-world evidence study.  Results from the CArdioREnal and MEtabolic (CaReMe) CKD study which was sponsored by AstraZeneca found that around 10% of the adult population… Read More

#News

#AstraZeneca #Clinical trials #Monoclonal antibodies

First patients dosed in trial for AstraZeneca’s Lupus treatment  

The first patients have been dosed in a Phase III clinical trial testing AstraZeneca’s treatment for lupus nephritis (LN).   The IRIS Phase III trial will be conducted in multiple countries across two years and is expected to enrol up to 360 participants aged between 18 and 70. Read More

#News

#AstraZeneca #Spinal cord injury #University of Birmingham

Researchers identify possible treatment for spinal cord injury 

An existing drug could help reduce spinal cord injury damage, scientists at the University of Birmingham have discovered.   A team of scientists from the University of Birmingham found that an enzyme inhibitor developed by AstraZeneca can significantly reduce ‘secondary damage’ caused by the body’s response to spinal… Read More

#News

#AstraZeneca #GSK #Malaria #University of Birmingham

This week in drug discovery (25-29 April)  

News round-up by DDW’s Reece Armstrong for 25-29 April     Q1 earnings, formulations to tackle blindness, liver cancer therapies and opportunities for malaria treatments are some of the themes of this week’s news round-up.  What’s behind GSK’s strong Q1 earnings?  DDW Deputy… Read More

#News